LivaNova Q3 revenue beats estimates on cardiopulmonary segment strength
Overview
UK medical device maker's Q3 revenue rose 9.9%, beating analyst expectations
Adjusted EPS for Q3 beat consensus, rising to $1.23
Company raised full-year 2026 revenue and adjusted EPS guidance
Outlook
LivaNova raises full-year 2026 revenue growth guidance to 9%-10% constant-currency, from 8%-9%
Company now expects full-year 2026 adjusted diluted EPS of $4.40-$4.50, up from $4.30-$4.40
Company maintains full-year 2026 adjusted free cash flow guidance at $140 mln to $160 mln
Result Drivers
CARDIOPULMONARY DEMAND - Co said Cardiopulmonary segment revenue rose 10.9%, driven by strong consumables demand and Essenz Perfusion System sales, as well as favorable realized price
NEUROMODULATION GROWTH - Neuromodulation segment revenue rose 11.1%, with growth across all regions, driven by higher volume and favorable realized price
OXYGENATOR CAPACITY EXPANSION - Co achieved operational production on new oxygenator manufacturing line to address strong customer demand
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $393.10 mln | $381.07 mln (9 Analysts) |
Q3 Adjusted EPS | Beat | $1.23 | $1.06 (9 Analysts) |
Q3 EPS | $0.11 |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for LivaNova PLC is $91.50, about 14.5% above its November 3 closing price of $79.90
The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 18 three months ago
Reuters Recommended Reads
Nov 4 - UK's Smith & Nephew misses Q3 revenue estimates, cuts outlook on slower US orthopaedics market
Nov 4 - Smith+Nephew cuts outlook after failed orthopaedics deal talks with J&J
Nov 2 - Denmark medical devices maker Coloplast's Q4 revenue rises
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)